Junctional Ectopic Tachycardia (JET)
Junctional ectopic tachycardia (JET) is a form of tachyarrhythmia that originates in the atrioventricular node and His bundle region. In most individuals, the mechanism for JET is believed to be enhanced normal automaticity. Protheragen is a foremost provider of research services focused on drug discovery and development for uncommon cardiovascular diseases, JET included. We take pride in providing integrated solutions that facilitate and expedite the transformation from bench to bedside.
Introduction to Junctional Ectopic Tachycardia (JET)
Junctional ectopic tachycardia (JET) is also named junctional tachycardia, focal tachycardia, or nonreentrant tachycardia. It is usually a tachycardia of narrow complex, though wide complex tachycardia with aberrant conduction may also occur. Arrhythmia can be classified as primary JET, without a clear predisposing factor, or secondary JET, which occurs in association with any condition. Congenital JET is exceptionally rare in infants and children.
Fig.1 Mechanism of JET. (Kylat, R. I., and Samson, R. A., 2019)Pathogenesis of Junctional Ectopic Tachycardia (JET)
Despite enhanced normal automaticity having been proposed as the explanation for JET under a large body of evidence, its mechanism remains unclear. Some suggest that abnormal automaticity and triggered activity may explain the arrhythmia in different contexts. Autoimmune and genetic factors have been suggested to account for congenital JET. Such positive family history is present in almost half of the individuals and is noted in some cases together with maternal lupus anti-SSA and anti-SSB.
Fig.2 Re-entrant tachycardia vs junctional tachycardia. (Yang, Q., et al., 2023)Therapeutics Development for Junctional Ectopic Tachycardia (JET)
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Dexmedetomidine | An alpha 2 adrenergic agonist decreases the incidence and duration of JET. | Alpha-2 adrenoreceptor | NCT05554848 | Phase IV |
| Ivabradine | Inhibits the If current in sinoatrial nodal tissue which decreases the rate of diastolic depolarization phase and the heart rate. | HCN channels | / | Approved |
| Amiodarone | Inhibits potassium currents in the cardiac myocardium and prolongs the action potential. | K+ channels | / | Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.
Our Services
In pursuit of innovative research, we carry out all phases of research with unmatched attention to detail and expertise, the integration of which has made it possible for us to render services that include everything from developing diagnostics to therapeutics. As the problem of uncommon cardiovascular diseases is highly specialized, we enable our partners to tackle such issues with a tailored approach that merges specialized disease model development and advanced research techniques.
Therapeutic Development Services
Animal Model Development for JET
Animal models analogously embody the pathophysiological attributes of JET, and therefore serve as a robust platform for studying the disease mechanisms and evaluating new therapy approaches. Our highly skilled professionals use state-of-the-art genetic modification, exacting surgical skills, and novel research techniques to create customized animal models specific to JET research.
These models can be surgically manipulated to induce tachyarrhythmias akin to JET, such as the open-heart surgery model.
The nodal-specific knockdown of Jph2 expression in mice results in an inducible atrioventricular nodal arrhythmia consistent with JET.
While pursuing excellence, Protheragen also strives to offer strong preclinical services. We conduct comprehensive pharmacokinetic analyses as well as stringent drug safety assessments, so all prospective therapies not only show efficacy but quality in safety standards as well. We provide bespoke solutions that demonstrate innovation and excellence, enabling success in drug development in a fast-tracked and effortless manner. If you are interested in our services, welcome inquiries and communications at all times regarding these services.
References
- Tchou, Patrick et al. "Junctional Tachycardia: A Critical Reassessment." JACC. Clinical electrophysiology 9.3 (2023): 425-441.
- Kylat, Ranjit I, and Ricardo A Samson. "Junctional ectopic tachycardia in infants and children." Journal of arrhythmia 36.1 59-66.
For research use only, not for clinical use.